

Cannabis Use and Cannabis Use Disorder among U.S. Adults with Psychiatric Disorders: 2001-2002 and 2012-2013

Authors: Deborah S. Hasin^{1,2,3}, PhD; Zachary L. Mannes³, PhD; Ofir Livne³, MD; David S. Fink³, PhD; Silvia S. Martins², MD, PhD; Malki Stohl³, MS; Mark Olfson¹, MD, MPH; Magdalena Cerdá⁴, DrPH; Katherine M. Keyes², PhD; Salomeh Keyhani^{5,6}, MD; Caroline G. Wisell³, MS; Julia M. Bujno³, BS; Andrew Saxon^{7,8,9}, MD

Affiliations:

¹ Columbia University Irving Medical Center, 630 West 168th Street, New York, NY 10032, USA

² Columbia University Mailman School of Public Health, 722 W 168th St, New York, NY 10032, USA

³ New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA

⁴ New York University, 50 West 4th Street, New York, NY 10012, USA

⁵ San Francisco VA Health System, 4150 Clement St, San Francisco, CA 94121, USA

⁶ University of California at San Francisco, 505 Parnassus Ave, San Francisco, CA 94143, USA

⁷ Health Services Research & Development (HSR&D) Seattle Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs Puget Sound Health Care System, 1660 S Columbian Way, Seattle, WA 98108, USA

⁸ Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Health Care

⁹ University of Washington School of Medicine, 1959 NE Pacific St, Seattle, WA 98195, USA

*Corresponding Author:

Deborah Hasin, Ph.D.

Columbia University/New York State Psychiatric Institute

1051 Riverside Drive, Box 123, New York, NY 10032

Phone: 646-774-7909; Fax: 646-774-7920

dsh2@cumc.columbia.edu; deborah.hasin@gmail.com

Abstract

Objective: Rates of cannabis use disorder (CUD) have increased disproportionately among Veterans Health Administration (VHA) patients with psychiatric disorders, but determining whether such an increase occurred more generally among U.S. adults requires nationally representative data.

Methods: Data came from 2001-2002 (n=43,093) and 2012-2013 (n=36,309) national surveys. Outcomes were any past-year non-medical cannabis use, frequent non-medical use (≥ 3 times weekly), and DSM-IV CUD. Psychiatric disorders included mood, anxiety disorders, antisocial personality disorder, and bipolar I. Logistic regressions were used to generate predicted marginal prevalences of the outcomes for each survey, risk differences calculated, and additive interaction tests determined whether between-survey differences in risk of cannabis outcomes differed between those with and without psychiatric conditions.

Results: Cannabis outcome prevalences increased more among those with than without any psychiatric disorder. The difference in prevalence differences included any past-year non-medical cannabis use, 2.45% (95%CI=1.29, 3.62); frequent non-medical cannabis use, 1.58% (95%CI=0.83, 2.33); CUD, 1.40% (95%CI=0.58, 2.21). For each specific disorder, prevalences increased more among those with the disorder, except CUD among those with antisocial personality disorder.

Conclusions: In the U.S. general population, rates of cannabis use and CUD increased at a greater rate among adults with psychiatric disorders, similar to findings from VHA patients. These results suggest that although VHA patients are not representative of all U.S. adults, findings from this important patient group can be informative. As U.S. cannabis use continues to expand, greater clinical and policy attention to CUD is needed for adults with psychiatric disorders.

Introduction

Over the last two decades, US adults' perception of risk in cannabis use has decreased¹⁻³ and cannabis use for medical or recreational purposes has been legalized in most U.S. states^{4,5}. Back in 2002, 10.4% of U.S. adults used cannabis and 1.5% had a diagnosis of Cannabis Use Disorder (CUD)⁶. By 2022, rates were sharply higher: 23.0% of U.S. adults had used cannabis in the past year and 6.9% had a past-year CUD diagnosis⁷. Thus, cannabis is one of the most widely-consumed psychoactive substances in the U.S.⁸, and CUD is a highly prevalent substance use disorder.

Although some individuals can use cannabis without harm, meta-analysis shows that approximately one-third of those who use cannabis regularly have CUD⁹, and prospective studies show that greater frequency of cannabis use at baseline substantially increases the risk of later CUD¹⁰. Additional adverse outcomes of cannabis use include psychiatric symptoms and disorders (e.g., anxiety, depression, psychosis)¹¹⁻¹⁴. While the direction of the relationship between cannabis use and psychiatric disorders is uncertain, the literature is clear that cannabis use and CUD occur at disproportionately high rates among those with psychiatric disorders.^{11,15} However, little is known about whether the increases over time in the prevalence of cannabis use and CUD are disproportionately greater in individuals with psychiatric disorders than among those without such disorders.

Ideally, determining whether rates of cannabis use and CUD increased disproportionately among those with diagnoses of specific psychiatric disorders would utilize data from nationally representative samples of the general population assessed repeatedly from several years ago to the current time. However, such data do not exist. A study addressing this question used 2005 to 2019 Veterans Health Administration (VHA) national electronic medical record patient data¹⁶. This study showed that rates of increase in CUD prevalence were substantially greater among patients with psychiatric disorders (e.g., depressive, anxiety, and bipolar disorders) than among patients with no psychiatric disorder.¹⁶ However, while the VHA is a national healthcare system, VHA patients are more likely to be male, older and socioeconomically disadvantaged than the U.S. adult general population¹⁷, and thus are not nationally representative. Because of this, findings on CUD prevalence trends in VHA patients may not be generalizable or applicable to others. To address this concern, we identified an additional source of data that was nationally representative, two nationally representative surveys of US adults conducted about 10 years apart. These surveys are the 2001–2002 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)¹⁸ and the 2012–2013 National Epidemiologic Survey on Alcohol and Related Conditions–III (NESARC-III)¹⁹. While these data are older, they enabled us to conduct a study comparing changes in the prevalence of non-medical cannabis use, frequent non-medical cannabis use, and CUD among adults in the US general population between participants with and without psychiatric diagnoses. We examined whether increases over time in non-medical cannabis use, frequent non-medical cannabis use (≥ 3 times weekly), and DSM-IV CUD were greater in participants with any of a set of common psychiatric disorders than in participants without such disorders, and then examined increases by specific disorders.

Methods

Sample and Procedures

NESARC protocols and consent procedures were approved by the institutional review boards at the US Bureau of the Census and the Office of Management and Budget; written consent was provided. The NESARC-III protocols and consent procedures were approved by institutional review boards at the National Institutes of Health and Westat; consent was verbal but recorded electronically, as approved by both institutional review boards. The NESARC¹⁸ and NESARC-III¹⁹ used similar multistage probability designs to create samples of adults age ≥ 18 living in households and group quarters²⁰. Each sample was independently ascertained. Both surveys were sponsored by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), who contracted the field work to large survey organizations (NESARC: US Census Bureau; NESARC-III: Westat). The total number of participants analyzed was 79,402 (NESARC $n=43,093$, NESARC-III $n=36,309$). Field procedures for both surveys were rigorously overseen by NIAAA staff^{21,22}, including sample recruitment, interviewer training (structured home-study, in-class training) and supervision by trained field supervisors, and random respondent callbacks to verify interview data. The methodological similarities of the two surveys have facilitated examination of change over time in numerous important health outcomes²²⁻²⁵. The NESARC response rate was 81.0%; the

protocol and written consent procedures were approved by US Bureau of the Census and Office of Management and Budget Institutional Review Boards (IRB). The NESARC-III response rate was 60.1%, similar to other contemporaneous nationally representative surveys^{26,27}. Sample weights adjusted for selection probabilities and nonresponse. The protocols and consent procedures (verbal, recorded electronically) were approved by IRBs at the National Institutes of Health and Westat.

Measures

The Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS), a structured computer-assisted diagnostic interview^{11,28-32}, was used to assess non-medical cannabis use, CUD, psychiatric disorders, and sociodemographic characteristics.²⁰ Study outcomes consisted of three past-year (past 12 months) cannabis variables: any non-medical use, frequent non-medical use, and DSM-IV cannabis use disorder (CUD). Non-medical use was defined as use without a prescription or other than prescribed, e.g., to get high²¹. Any use was defined as ≥ 1 time in the past 12 months, and frequent use as ≥ 3 times weekly. CUD was defined as meeting criteria for DSM-IV cannabis dependence or abuse, as has been reported previously.²² These two disorders were combined because their criteria reflect a single condition³³. Most of the 22 CUD symptom items used in both surveys were identical; examination of the few slight differences showed that they could not account for the large differences in prevalence in the two surveys^{21,22}.

The psychiatric disorders analyzed in the present study included depressive disorders (major depressive disorder, dysthymia), anxiety disorders, antisocial personality disorder, and bipolar I disorder. Any anxiety disorder included panic disorder with and without agoraphobia, social phobia, specific phobia, and generalized anxiety disorder. All psychiatric diagnoses excluded substance- and medically-induced disorders. For each individual psychiatric disorder, a binary variable was created to include only those with the disorder and those without *any* of the listed psychiatric disorders. A variable was also created to represent any psychiatric disorder (APD) vs. none.

Multiple versions of the AUDADIS, including those used in the NESARC and NESARC-III, have been subjected to rigorous reliability testing^{11,28-32}. Most recently, in a general population sample, test-retest reliability of 12-month cannabis use was substantial ($\kappa=0.78$)²⁸, and test-retest reliability of CUD ($\kappa=0.41$) and its dimensional criteria scale (intraclass correlation coefficient=0.70) was fair to substantial in a general population³⁴. Validity of CUD was assessed through blind clinician re-appraisal using the semi-structured, clinician-administered Psychiatric Research Interview for Substance and Mental Disorders (PRISM)³⁵ in a separate general population sample. AUDADIS/PRISM concordance was moderate for cannabis use disorder ($\kappa=0.60$) and substantial for its dimensional criteria scale (ICC=0.79). Reliability and validity of depressive and anxiety disorder diagnoses was fair to moderate.

Study control covariates included respondent gender (male, female); age (18-29; 30-44; 45-64; ≥ 65 years); race/ethnicity (Hispanic; Non-Hispanic White and Black; Native American; Asian/Pacific Islander); education (<high school; high school graduate or GED; \geq some college); marital status (married or living together; separated/widowed/divorced; never married); family income ($\$0$ - $\$19,999$; $\$20,000$ - $\$34,999$; $\$35,000$ - $\$69,999$; $\geq \$70,000$).

Statistical Analysis

NESARC and NESARC-III data sets were concatenated. To evaluate trends between the two surveys, a survey indicator variable was added. We used logistic regressions to model cannabis outcomes as a function of psychiatric disorder, survey, and psychiatric disorder by survey interactions, with control covariates including sociodemographic characteristics (age, race/ethnicity, gender, education, marital status, income) and covariate-by-psychiatric disorder interactions, which allow covariate effects to differ between those with and without psychiatric disorders. For each cannabis outcome, predictions from the logistic models were used to generate predicted marginal prevalences of the cannabis outcomes in each survey (prevalences standardized to the distribution of sociodemographic characteristics of the sample pooled across the two surveys) by psychiatric disorder status (yes/no). Risk differences were calculated for between-survey comparisons (2001-2002 compared with 2012-2013) within each psychiatric disorder group (i.e. those with and without any psychiatric disorder, and then each psychiatric disorder). Interaction on the additive scale tested whether the difference in

absolute risk of each cannabis outcome between surveys differed between those with and without each psychiatric disorder (difference in risk differences, or DiD). Interactions on the additive scale were evaluated because they indicate groups with the greatest population-level risk, or changes in risk, and thus can be considered most informative from a public health perspective. To conduct the analyses, SUDAAN v.11.0.4 was used, incorporating survey weights to adjust for the complex sampling design and to yield U.S. adult population-representative estimates. Estimates for risk differences and 95% confidence intervals were obtained using the PRED_EFF option in SUDAAN. Statistical tests were two-tailed, with significance based on $p < 0.05$, as indicated by 95% confidence intervals. For difference effects, a value of 0.0 indicates no difference, so an estimate with a 95% confidence interval that does not include 0.0 is statistically significant at $p < 0.05$.

Results

Sample characteristics are shown in Table 1. The samples had similar distributions across sociodemographic groups. In 2001-2002, 19.07% (standard error [SE]=0.14) had any psychiatric disorder (APD) as defined for this study, while in 2012-2013, 23.99% (SE=0.38) had APD.

Increases in cannabis outcomes by Any Psychiatric Disorder (APD; yes vs. no): Table 2

Among those with APD, any non-medical cannabis use increased from 8.03% in 2001-2002 to 15.25% in 2012-2013, an increase of 7.22%. Among those without APD, the increase was from 2.90% in 2001-2002 to 7.67% in 2012-2013, an increase of 4.77%. The difference in prevalence differences (DiD) between the two surveys, 2.45%, indicated a significantly greater increase in any non-medical use among those with APD. Frequent non-medical use among those with APD increased from 2.84% in 2001-2002 to 6.46% in 2012-2013, an increase of 3.62%. Among those without APD, the increase was from 0.68% in 2001-2002 to 2.72% in 2012-2013, an increase of 2.04%. The DiD estimate, 1.58%, indicated a significantly greater increase in frequent non-medical use among those with APD. Past-year CUD increased among those with APD from 3.36% in 2001-2002 to 5.79% in 2012-2013, an increase of 2.43%. Among those without APD, past-year CUD increased from 0.88% in 2001-2002 to 1.91% in 2012-2013, an increase of 1.04%. The DiD estimate, 1.40%, indicated a significantly greater absolute increase in CUD among those with APD.

Increases in cannabis outcomes by specific psychiatric disorders: Table 3

Any non-medical cannabis use. There was a significant increase in the prevalence of any past-year non-medical cannabis use between 2001-2002 and 2012-2013 among those with each psychiatric disorder (from 7.14% to 8.74%) and among those without any psychiatric disorders (from 4.63% to 4.71%). For all diagnoses, the increases were significantly greater among those with each of the psychiatric disorders than among those without the specific disorder (difference in prevalence difference, 2.46% to 4.14%).

Frequent non-medical cannabis use. There were significant increases in the prevalence of frequent non-medical cannabis use between 2001-2002 and 2012-2013 among both those with each psychiatric disorder (from 3.60 to 5.49%) and those without disorder (from 1.97% to 2.03%). The increase among those with each psychiatric disorder was significantly greater than the increase among those without the disorder (difference in prevalence difference, 1.61% to 3.46%).

DSM-IV CUD. The prevalence of CUD increased significantly between 2001-2002 and 2012-2013 among those with each psychiatric disorder (2.14% to 3.82%) and among those without any psychiatric disorder (1.00% to 1.04%). With the exception of antisocial personality disorder, the increase among those with each psychiatric disorder was significantly greater than the increase among those without the disorder (difference in prevalence difference, from 1.47% to 2.80%).

Discussion

This study utilized data from two U.S. nationally representative cross-sectional adult surveys conducted approximately 10 years apart (2001-2002 and 2012-2013) to determine whether increases over time in any past-year non-medical cannabis use, frequent non-medical cannabis use, and cannabis use disorder (CUD) were disproportionately greater among participants with past-year psychiatric disorders versus those without such conditions. The disorders examined were those measured in both surveys, i.e., major depressive disorder and dysthymia, panic disorder with and without agoraphobia, social phobia, specific phobia, generalized anxiety disorder, antisocial personality disorder and bipolar I disorder, as well as a summary variable indicating that one or more of the disorders was present. For any non-medical cannabis use and frequent non-medical cannabis

use (≥ 3 times per week), prevalence increases were greater among those with any psychiatric disorder vs. none, as well as for each of the psychiatric disorders considered separately. For CUD, prevalence increases were greater among those with all psychiatric disorders examined (except antisocial personality disorder), compared to those with none of the psychiatric disorders.

This study was undertaken to explore whether the disproportionate increases in CUD rates among VHA patients with psychiatric disorders, who are more likely to be male, older, White, and have lower income than the U.S. adult general population, would also be found in samples of individuals who were representative of U.S. adult population as a whole. The present results are indeed similar to results found when comparing time trends in the prevalence of CUD between 2005 and 2019 between VHA patients with and without diagnosed psychiatric disorders¹⁶. In that study, CUD rates also had disproportionately greater increases among patients with psychiatric disorders compared to patients without such disorders. In both studies, the repeated cross-sectional nature of the analysis precluded determining the direction of effect between psychiatric disorders and the cannabis outcomes. However, both sets of results are consistent with an explanation that greater use of cannabis increased the risk for psychiatric symptoms and/or disorders, or that individuals with psychiatric symptoms/disorders increased their use of cannabis to self-medicate the symptoms. To disentangle the direction of effect, fine-grained longitudinal cohort analyses are needed. Such an analysis could potentially be conducted with VHA electronic medical record data. While outside the scope of the present study, this should be done in the future.

Study limitations are noted. NESARC-III are now 12 years old and do not extend into the years of recreational cannabis except for the earliest years in Colorado and Washington. Also, since 2012-2013, the potency of illicitly purchased cannabis has increased, and highly potent legal cannabis products are increasingly available. If another NESARC survey had been conducted around 2020-2022, a similar analysis would reflect more recent changes, but no NESARC surveys were conducted after 2012-2013, precluding such work. Post-traumatic stress disorder (PTSD) was not included because it was not assessed in the 2001-2002 NESARC. Psychotic-spectrum disorders were not included because (a) they were not assessed in detail in the NESARC surveys and (b) an analysis of the relationship of CUD to a self-reported psychosis variable in NESARC surveys has already been reported³⁶. DSM-5 CUD diagnoses were not analyzed because not all DSM-5 CUD criteria were not assessed in the 2001-2002 NESARC. Depressive and anxiety disorders were diagnosed using DSM-IV criteria in NESARC and DSM-5 criteria in NESARC-III. While rates of major depressive disorder were higher in NESARC-III than in NESARC (Table 1), the minimal changes in the diagnostic criteria did not appear to account for such increases³⁷. We note that changing diagnostic criteria are also issues in long-term trend studies using VHA data, which transitioned from ICD-9-CM to ICD-10-CM in 2015. However, despite the changes in nomenclatures across both studies, their findings on disproportionate increases in cannabis outcomes among individuals with psychiatric disorders were consistent. Additionally, all NESARC and NESARC-III data were based on self-report and biological measures were not used. Also, similar to other national surveys, some population segments were not covered in either survey (e.g., homeless and incarcerated individuals), potentially leading to underestimation. Finally, cannabis use variables could have appeared to increase due to reductions in stigma leading to greater reporting over time. However, our findings that urine toxicology tests positive for cannabis in VHA patients also increased over time³⁸ suggests that the increases in prevalence of the self-reported cannabis measures in both datasets were not entirely due to reduced stigma of cannabis use.³⁸

In conclusion, this study adds to evidence that the adult prevalences of any past-year non-medical use, frequent non-medical use and CUD are increasing faster among individuals with psychiatric disorders than among individuals without psychiatric disorders. The consistency of findings between the older data from representative samples of adults in the general population with the more recent findings on data across among veteran patients treated at the VHA supports the validity of each, and suggests that information gleaned from VHA data may have applicability and utility to patient groups beyond those treated by the VHA. At this stage, factors contributing to the disproportionate increases among those with psychiatric disorders should be sought. Possibilities include changing attitudes towards the efficacy of cannabis to treat psychiatric symptoms such as insomnia, anxiety or chronic pain (which is highly correlated with psychiatric conditions). Another potential contributor consists of the declines in availability of prescribed medications formerly used to treat such symptoms, e.g., opioids, sedatives/hypnotics and anxiolytics, causing a shift to cannabis use and among a vulnerable subset, development of CUD. The findings also provide additional evidence that clinician and policymaker attention to the increasing risks of non-medical cannabis use and CUD among those with psychiatric problems is needed.

References

1. Compton WM, Han B, Jones CM, Blanco C, Hughes A. Marijuana use and use disorders in adults in the USA, 2002-14: analysis of annual cross-sectional surveys. *Lancet Psychiatry*. 2016;3(10):954-964.
2. Pacek LR, Mauro PM, Martins SS. Perceived risk of regular cannabis use in the United States from 2002 to 2012: differences by sex, age, and race/ethnicity. *Drug Alcohol Depend*. 2015;149:232-244.
3. Substance Abuse and Mental Health Services Administration. 2022 NSDUH Detailed Tables: Table 3.1A – Perceived Great Risk of Harm Associated with Substance Use and Perceived Availability of Substances: Among People Aged 12 or Older; by Age Group, Numbers in Thousands, 2021 and 2022. 2023; <https://www.samhsa.gov/data/sites/default/files/reports/rpt42728/NSDUHDetailedTabs2022/NSDUHDetailedTabs2022/NSDUHDetTabsSect3pe2022.htm#tab3.1a>. Accessed Jan 18, 2024.
4. NORML. State Laws. <https://norml.org/laws/>. Accessed Jan 18, 2024.
5. ProCon.org. State-by-State Medical Marijuana Laws. 2023; <https://medicalmarijuana.procon.org/legal-medical-marijuana-states-and-dc/>. Accessed Jan 18, 2024.
6. Compton WM, Han B, Jones CM, Blanco C. Cannabis use disorders among adults in the United States during a time of increasing use of cannabis. *Drug Alcohol Depend*. 2019;204:107468.
7. Substance Abuse and Mental Health Services Administration. 2022 NSDUH Detailed Tables. 2023; <https://www.samhsa.gov/data/report/2022-nsduh-detailed-tables>. Accessed Jan 18, 2024.
8. Hasin DS. US Epidemiology of Cannabis Use and Associated Problems. *Neuropsychopharmacology*. 2018;43(1):195-212.
9. Leung J, Chan GCK, Hides L, Hall WD. What is the prevalence and risk of cannabis use disorders among people who use cannabis? a systematic review and meta-analysis. *Addict Behav*. 2020;109:106479.
10. Robinson T, Ali MU, Easterbrook B, Coronado-Montoya S, Daldegan-Bueno D, Hall W, Jutras-Aswad D, Fischer B. Identifying risk-thresholds for the association between frequency of cannabis use and development of cannabis use disorder: A systematic review and meta-analysis. *Drug Alcohol Depend*. 2022;238:109582.
11. Hasin DS, Kerridge BT, Saha TD, Huang B, Pickering R, Smith SM, Jung J, Zhang H, Grant BF. Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012-2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. *Am J Psychiatry*. 2016;173(6):588-599.
12. Stinson FS, Ruan WJ, Pickering R, Grant BF. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. *Psychol Med*. 2006;36(10):1447-1460.
13. Solmi M, De Toffol M, Kim JY, Choi MJ, Stubbs B, Thompson T, Firth J, Miola A, Croatto G, Baggio F, Michelson S, Ballan L, Gerdle B, Monaco F, Simonato P, Scocco P, Ricca V, Castellini G, Fornaro M, Murru A, Vieta E, Fusar-Poli P, Barbui C, Ioannidis JPA, Carvalho AF, Radua J, Correll CU, Cortese S, Murray RM, Castle D, Shin JI, Dragioti E. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. *BMJ*. 2023;382:e072348.
14. Petrilli K, Ofori S, Hines L, Taylor G, Adams S, Freeman TP. Association of cannabis potency with mental ill health and addiction: a systematic review. *Lancet Psychiatry*. 2022;9(9):736-750.
15. Lev-Ran S, Imtiaz S, Rehm J, Le Foll B. Exploring the association between lifetime prevalence of mental illness and transition from substance use to substance use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions (NESARC). *Am J Addict*. 2013;22(2):93-98.
16. Livne O, Malte CA, Olfson M, Wall MM, Keyes KM, Maynard C, Gradus JL, Saxon AJ, Martins SS, Keyhani S, McDowell Y, Fink DS, Mannes ZL, Gutkind S, Hasin DS. Trends in Prevalence of Cannabis Use Disorder Among U.S. Veterans With and Without Psychiatric Disorders Between 2005 and 2019. *Am J Psychiatry*. 2023:appiajp20230168.
17. Fink DS, Stohl M, Mannes ZL, Shmulewitz D, Wall M, Gutkind S, Olfson M, Gradus J, Keyhani S, Maynard C, Keyes KM, Sherman S, Martins S, Saxon AJ, Hasin DS. Comparing mental and physical health of U.S. veterans by VA healthcare use: implications for generalizability of research in the VA electronic health records. *BMC Health Serv Res*. 2022;22(1):1500.
18. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry*. 2004;61(8):807-816.

19. Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, Pickering RP, Ruan WJ, Smith SM, Huang B, Hasin DS. Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. *JAMA Psychiatry*. 2015;72(8):757-766.
20. Hasin DS, Shmulewitz D, Cerda M, Keyes KM, Olfson M, Sarvet AL, Wall MM. U.S. Adults With Pain, a Group Increasingly Vulnerable to Nonmedical Cannabis Use and Cannabis Use Disorder: 2001-2002 and 2012-2013. *Am J Psychiatry*. 2020;177(7):611-618.
21. Hasin DS, Sarvet AL, Cerda M, Keyes KM, Stohl M, Galea S, Wall MM. US Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana Laws: 1991-1992 to 2012-2013. *JAMA Psychiatry*. 2017;74(6):579-588.
22. Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, Jung J, Pickering RP, Ruan WJ, Smith SM, Huang B, Grant BF. Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013. *JAMA Psychiatry*. 2015;72(12):1235-1242.
23. Martins SS, Sarvet A, Santaella-Tenorio J, Saha T, Grant BF, Hasin DS. Changes in US lifetime heroin use and heroin use disorder: Prevalence from the 2001-2002 to 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions. *JAMA Psychiatry*. 2017;74(5):445-455.
24. Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, Huang B, Jung J, Zhang H, Fan A, Hasin DS. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001-2002 to 2012-2013: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *JAMA Psychiatry*. 2017;74(9):911-923.
25. Olfson M, Blanco C, Wall M, Liu SM, Saha TD, Pickering RP, Grant BF. National trends in suicide attempts among adults in the United States. *JAMA Psychiatry*. 2017;74(11):1095-1103.
26. Substance Abuse and Mental Health Services Administration. *Results from the 2012 National Survey on Drug Use and Health: Summary of national findings. Appendix B: Statistical methods and measurement*. Rockville, MD: U.S. Department of Health and Human Services;2013. NSDUH Series H-46, HHS Publication No. (SMA) 13-4795.
27. Adams PF, Kirzinger WK, Martinez M. Summary health statistics for the U.S. population: National Health Interview Survey, 2012. *Vital Health Stat 10*. 2013(259):1-95.
28. Grant BF, Harford TC, Dawson DA, Chou PS, Pickering RP. The Alcohol Use Disorder and Associated Disabilities Interview schedule (AUDADIS): reliability of alcohol and drug modules in a general population sample. *Drug Alcohol Depend*. 1995;39(1):37-44.
29. Ustun B, Compton W, Mager D, Babor T, Baiyewu O, Chatterji S, Cottler L, Gogus A, Mavreas V, Peters L, Pull C, Saunders J, Smeets R, Stipek MR, Vrsti R, Hasin D, Room R, Van den Brink W, Regier D, Blaine J, Grant BF, Sartorius N. WHO Study on the reliability and validity of the alcohol and drug use disorder instruments: overview of methods and results. *Drug Alcohol Depend*. 1997;47(3):161-169.
30. Chatterji S, Saunders JB, Vrsti R, Grant BF, Hasin D, Mager D. Reliability of the alcohol and drug modules of the Alcohol Use Disorder and Associated Disabilities Interview Schedule--Alcohol/Drug-Revised (AUDADIS-ADR): an international comparison. *Drug Alcohol Depend*. 1997;47(3):171-185.
31. Grant BF, Dawson DA, Stinson FS, Chou PS, Kay W, Pickering R. The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV): reliability of alcohol consumption, tobacco use, family history of depression and psychiatric diagnostic modules in a general population sample. *Drug Alcohol Depend*. 2003;71(1):7-16.
32. Canino G, Bravo M, Ramirez R, Febo VE, Rubio-Stipek M, Fernandez RL, Hasin D. The Spanish Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): reliability and concordance with clinical diagnoses in a Hispanic population. *J Stud Alcohol*. 1999;60(6):790-799.
33. Hasin DS, O'Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, Compton WM, Crowley T, Ling W, Petry NM, Schuckit M, Grant BF. DSM-5 criteria for substance use disorders: Recommendations and rationale. *Am J Psychiatry*. 2013;170(8):834-851.
34. Grant BF, Goldstein RB, Smith SM, Jung J, Zhang H, Chou SP, Pickering RP, Ruan WJ, Huang B, Saha TD, Aivadyan C, Greenstein E, Hasin DS. The Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5): reliability of substance use and psychiatric disorder modules in a general population sample. *Drug Alcohol Depend*. 2015;148:27-33.
35. Hasin DS, Shmulewitz D, Stohl M, Greenstein E, Aivadyan C, Morita K, Saha T, Aharonovich E, Jung J, Zhang H, Nunes EV, Grant BF. Procedural validity of the AUDADIS-5 depression, anxiety and post-traumatic stress disorder modules: Substance abusers and others in the general population. *Drug Alcohol Depend*. 2015;152:246-256.

36. Livne O, Shmulewitz D, Sarvet AL, Wall MM, Hasin DS. Association of Cannabis Use-Related Predictor Variables and Self-Reported Psychotic Disorders: U.S. Adults, 2001-2002 and 2012-2013. *Am J Psychiatry*. 2022;179(1):36-45.
37. Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, Grant BF. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. *JAMA Psychiatry*. 2018;75(4):336-346.
38. Fink DS, Malte C, Cerda M, Mannes ZL, Livne O, Martins SS, Keyhani S, Olfson M, McDowell Y, Gradus JL, Wall MM, Sherman S, Maynard CC, Saxon AJ, Hasin DS. Trends in Cannabis-positive Urine Toxicology Test Results: US Veterans Health Administration Emergency Department Patients, 2008 to 2019. *J Addict Med*. 2023;17(6):646-653.

Table 1. Characteristics of the two survey samples

	NESARC (N=43,093) 2001-2002		NESARC-III (N=36,309) 2012-2013	
	n	% (SE)	n	% (SE)
Demographics				
<i>Sex</i>				
Men	18518	47.92 (0.15)	15862	48.09 (0.30)
Women	24575	52.08 (0.15)	20447	51.91 (0.30)
<i>Age</i>				
18-29	8666	21.80 (0.16)	8126	21.67 (0.36)
30-44	13382	30.89 (0.16)	10135	25.73 (0.33)
45-64	12840	31.06 (0.14)	12242	35.03 (0.32)
65+	8205	16.24 (0.10)	5806	17.57 (0.37)
<i>Race/ethnicity</i>				
White	24507	70.89 (0.21)	19194	66.19 (0.77)
Black	8245	11.07 (0.17)	7766	11.79 (0.66)
Native American	701	2.12 (0.09)	511	1.56 (0.12)
Asian or Pacific Islander	1332	4.36 (0.05)	1801	5.73 (0.47)
Hispanic	8308	11.56 (0.10)	7037	14.74 (0.67)
<i>Annual Family Income</i>				
\$0-\$19,999	12602	23.55 (0.15)	10631	22.80 (0.50)
\$20,000-\$34,999	9401	20.19 (0.12)	7854	18.93 (0.35)
\$35,000-\$69,999	12943	32.13 (0.13)	9562	27.21 (0.33)
\$70,000+	8147	24.12 (0.12)	8262	31.06 (0.66)
<i>Education level</i>				
Less than high school	7849	15.65 (0.13)	5490	13.01 (0.42)
High school	12547	29.33 (0.17)	9799	25.78 (0.51)
Some college or more	22697	55.02 (0.21)	21020	61.21 (0.76)
<i>Marital status</i>				
Married/living together	22081	61.62 (0.14)	16794	57.83 (0.51)
Separated/widowed/divorced	11117	17.46 (0.11)	9423	19.66 (0.32)
Never married	9895	20.92 (0.16)	10092	22.52 (0.44)
<i>Psychiatric disorders</i>				
Any of the below disorders	8218	19.07 (0.14)	8870	23.99 (0.38)
Major Depression	2422	5.47 (0.16)	3963	10.39 (0.25)
Any Depressive Disorder (major depression or dysthymia)	2653	5.93 (0.16)	5357	14.05 (0.29)
Any Anxiety Disorder	4886	11.37 (0.33)	4701	13.07 (0.24)
Antisocial Personality Disorder	1422	3.63 (0.15)	1600	4.33 (0.16)
Bipolar 1 Disorder	1411	3.31 (0.13)	753	2.07 (0.10)

Table 2. Any non-medical cannabis use, frequent non-medical use, and DSM-IV Cannabis Use Disorder among U.S. adults with and without Any Psychiatric Disorder (APD), 2001–2002 and 2012–2013: Predicted prevalences and between survey and APD group comparisons^a

	Participants With Any Psychiatric Disorder				Participants Without Any Psychiatric Disorder				Difference in PD ^c	
	2001-2002	2012-2013	Prevalence difference ^b		2001-2002	2012-2013	Prevalence difference ^b			
Cannabis Outcome, past year	% (SE)	% (SE)	% (95% CI)	p-value	% (SE)	% (SE)	% (95% CI)	p-value	% (95% CI)	p-value
Any Non-medical Use ^d	8.03 (0.41)	15.25 (0.49)	7.22 (6.00, 8.45)	<.0001	2.90 (0.12)	7.67 (0.24)	4.77 (4.25, 5.29)	<.0001	2.45 (1.29, 3.62)	0.0001
Frequent^e Non-medical Use	2.84 (0.23)	6.46 (0.33)	3.62 (2.85, 4.39)	<.0001	0.68 (0.06)	2.72 (0.13)	2.04 (1.76, 2.32)	<.0001	1.58 (0.83, 2.33)	0.0001
DSM-IV Cannabis Use Disorder	3.36 (0.26)	5.79 (0.32)	2.43 (1.64, 3.23)	<.0001	0.88 (0.06)	1.91 (0.12)	1.04 (0.78, 1.30)	<.0001	1.40 (0.58, 2.21)	0.0009

^a Data are from the 2001–2002 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) survey and the 2012–2013 NESARC-III survey. All estimates are adjusted for sociodemographic covariates (age, gender, race/ ethnicity, education level, marital status, and family income).

^b Prevalence differences with 95% confidence intervals that do not include 0.0 are statistically significant at p<0.05.

^c Additive interaction: differences in prevalence differences whose 95% confidence intervals do not include 0.0 are statistically significant at p<0.05.

^d Nonmedical use was defined as cannabis use without a prescription or other than prescribed, for example, to get high.

^e Frequent use was defined as cannabis use at least three times a week.

Table 3: Any non-medical cannabis use, frequent non-medical use, and DSM-IV Cannabis Use Disorder among U.S. adults U.S. adults with and without psychiatric disorders, 2001–2002 and 2012–2013. Predicted prevalences and between survey and psychiatric disorder group comparisons^a

Psychiatric Disorder	With Disorder				Without Disorder				Difference in PD ^c	
	2001-2002	2012-2013	Prevalence difference ^b		2001-2002	2012-2013	Prevalence difference ^b			
	Past Year Any Non-medical Use^d									
Major Depression	6.94 (0.65)	14.47 (0.61)	7.52 (5.86, 9.19)	<.0001	2.83 (0.11)	7.49 (0.24)	4.66 (4.15, 5.17)	<.0001	2.86 (1.18, 4.55)	0.0010
Any Depressive Disorder ^f	6.98 (0.64)	15.72 (0.67)	8.74 (6.99, 10.49)	<.0001	2.84 (0.12)	7.52 (0.24)	4.68 (4.17, 5.19)	<.0001	4.06 (2.33, 5.79)	<.0001
Any Anxiety Disorder	7.00 (0.50)	14.35 (0.63)	7.35 (5.86, 8.83)	<.0001	2.80 (0.11)	7.43 (0.24)	4.63 (4.12, 5.13)	<.0001	2.72 (1.24, 4.20)	0.0004
Antisocial Personality Disorder	15.21 (1.15)	23.41 (1.03)	8.20 (5.19, 11.21)	<.0001	2.87 (0.12)	7.58 (0.24)	4.71 (4.20, 5.23)	<.0001	3.49 (0.55, 6.43)	0.0212
Bipolar 1 Disorder	10.49 (0.86)	19.27 (1.55)	8.78 (5.41, 12.15)	<.0001	2.82 (0.11)	7.46 (0.24)	4.64 (4.14, 5.15)	<.0001	4.14 (0.82, 7.46)	0.0155
	Past Year Frequent^e Non-medical Use									
Major Depression	1.42 (0.24)	5.66 (0.44)	4.24 (3.29, 5.19)	<.0001	0.66 (0.05)	2.64 (0.13)	1.98 (1.71, 2.26)	<.0001	2.26 (1.30, 3.22)	<.0001
Any Depressive Disorder ^f	1.48 (0.23)	6.45 (0.45)	4.96 (3.99, 5.93)	<.0001	0.66 (0.05)	2.65 (0.13)	1.99 (1.72, 2.27)	<.0001	2.97 (2.02, 3.92)	<.0001
Any Anxiety Disorder	2.36 (0.30)	6.24 (0.46)	3.89 (2.87, 4.90)	<.0001	0.65 (0.05)	2.62 (0.13)	1.97 (1.70, 2.24)	<.0001	1.92 (0.92, 2.92)	0.0002
Antisocial Personality Disorder	6.29 (0.67)	11.78 (0.77)	5.49 (3.53, 7.45)	<.0001	0.68 (0.06)	2.71 (0.13)	2.03 (1.76, 2.31)	<.0001	3.46 (1.51, 5.40)	0.0006
Bipolar 1 Disorder	4.25 (0.69)	9.46 (0.92)	5.21 (3.02, 7.39)	<.0001	0.66 (0.05)	2.65 (0.13)	1.99 (1.71, 2.26)	<.0001	3.22 (1.04, 5.39)	0.0042
	Past Year DSM-IV Cannabis Use Disorder									
Major Depression	2.61 (0.37)	5.60 (0.44)	2.99 (1.89, 4.10)	<.0001	0.85 (0.06)	1.87 (0.11)	1.01 (0.76, 1.27)	<.0001	1.98 (0.84, 3.12)	0.0008
Any Depressive Disorder ^f	2.70 (0.37)	6.37 (0.48)	3.67 (2.52, 4.83)	<.0001	0.86 (0.06)	1.87 (0.11)	1.02 (0.76, 1.27)	<.0001	2.66 (1.48, 3.84)	<.0001
Any Anxiety Disorder	2.95 (0.32)	5.51 (0.44)	2.56 (1.53, 3.59)	<.0001	0.84 (0.06)	1.85 (0.11)	1.00 (0.75, 1.25)	<.0001	1.56 (0.53, 2.58)	0.0034
Antisocial Personality Disorder	7.15 (0.71)	9.29 (0.82)	2.14 (0.05, 4.23)	0.0459	0.88 (0.06)	1.92 (0.12)	1.04 (0.78, 1.30)	<.0001	1.10 (-0.99, 3.20)	0.3044
Bipolar 1 Disorder	5.12 (0.64)	8.94 (0.99)	3.82 (1.57, 6.07)	0.0011	0.86 (0.06)	1.88 (0.12)	1.02 (0.76, 1.27)	<.0001	2.80 (0.52, 5.09)	0.0173

^a Data are from the 2001–2002 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) survey and the 2012–2013 NESARC-III survey. All estimates are adjusted for sociodemographic covariates (age, gender, race/ ethnicity, education level, marital status, and family income).

^b Prevalence differences with 95% confidence intervals that do not include 0.0 are statistically significant at p<0.05.

^c Additive interaction: differences in prevalence differences whose 95% confidence intervals do not include 0.0 are statistically significant at p<0.05.

^d Nonmedical use was defined as cannabis use without a prescription or other than prescribed, for example, to get high.

^e Frequent use was defined as cannabis use at least three times a week.

^f Includes Major Depressive Disorder or Dysthymia